Protein kinase C mediates the effects of delta-opioid receptor stimulation on survival and apoptosis in neonatal cardiomyocytes cultured in serum-deprived condition.
The aims of the present study were to determine whether Delta opioid receptor (delta-OR) stimulation improved the survival of cardiomyocytes cultured in serum-deprived conditions, which impaired their growth. [D-Ala2, D-Leu5]-enkephalin (DADLE), a selective delta-OR agonist, at a concentration range of 0.1 micromol/L to 10 micromol/L for 48 h increased the viability of the cardiomyocyte under serum deprivation conditions. DADLE (0.1 micromol/L) also decreased the early cell apoptosis rate and the expression of Caspase-3. The effects of 0.1 micromol/L DADLE were abolished by 10 micromol x L(-1) naltrindole, a selective delta-OR antagonist, or by blockade of protein kinase C (PKC) with its blockers, 10 micromol x L(-1) GF109203X or 1 micromol/L staurosporine. Furthermore, 0.1 micromol x L(-1) DADLE increased the expression of PKC, an effect abrogated by 10 micromol x L(-1) naltrindole. The observations indicate that delta-OR stimulation improves the viability and reduces the apoptosis via PKC pathway in neonatal cardiomyocytes cultured in serum deprived conditions.
Wang
Dapeng
D
Key Laboratory of Molecular Biology & Drug Research, Liaoning Medical College, Liaoning, 121001 Jinzhou, China.
Wang
Hongxin
H
Wu
Guoqiang
G
Yang
Yuhong
Y
Yang
Jing
J
Liu
Chunna
C
Wong
Tak Ming
TM
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D002470:Cell Survival; D002478:Cells, Cultured; D004396:Coloring Agents; D016895:Culture Media, Serum-Free; D004247:DNA / Q000096:biosynthesis / Q000235:genetics; D016308:Enkephalin, Leucine-2-Alanine / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D007211:Indoles / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D032383:Myocytes, Cardiac / Q000502:physiology*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000819:agonists*; D015398:Signal Transduction / Q000187:drug effects
D004396:Coloring Agents; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D009270:Naloxone; D016308:Enkephalin, Leucine-2-Alanine; D004247:DNA; D011493:Protein Kinase C; C070515:bisindolylmaleimide I